

---

# **A<sup>PhA</sup>** **DrugInfoLine<sup>®</sup>**

**December 2018**

## [Neurology](#)

Advising on this article: Jack J. Chen

**December 3, 2018**

# **Switching antiepileptic suppliers associated with increased seizure risk?**

## **Key Point**

Switching the manufacturer of antiepileptic drugs increased the risk of seizure recurrence in patients who were previously seizure-free, according to a retrospective, observational study published in the Annals of Neurology.

## **Source URL:**

<http://www.aphadruginfoline.com/neurology/switching-antiepileptic-suppliers-associated-increased-seizure-risk>

## [Focus on Asthma Care](#)

Advising on this article: Devra K. Dang

**December 3, 2018**

# **SMART therapy associated with a lower risk of asthma exacerbations**

## **Key Point**

A meta-analysis of 16 trials evaluating use of a single maintenance and reliever therapy (SMART), with the majority of studies using a combination of budesonide and formoterol in a dry-powder inhaler, found that the risk of asthma exacerbations was lower in patients using this regimen compared with an inhaled corticosteroid (ICS) as the controller therapy (with or without a long-acting beta-agonist [LABA]) plus a short-acting beta-agonist (SABA) as the relief therapy.

## **Source URL:**

<http://www.aphadruginfoline.com/focus-asthma-care/smart-therapy-associated-lower-risk-asthma-exacerbations>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.